>>>TREATMENT, Metabolic Dysfunctions associated with pharmacological treatment of Schizophrenia.

TREATMENT, Metabolic Dysfunctions associated with pharmacological treatment of Schizophrenia.

H2020-MSCA-ITN-2016

TREATMENT is an European project in consortium in which NIMGenetics participates to carry out the identification and clinical validation of biomarkers with predictive value for metabolic complications associated with drug treatments for schizophrenia. The consortium is structured as an ITN -Innovative Training Network- with the purpose of training new generations of researchers capable of transforming innovative ideas into products and services. As a result of the project, a platform of biomarkers clinically useful in patients with schizophrenia undergoing prolonged pharmacological treatments will be obtained.

2018-12-17T16:55:09+00:0012 December , 2018|